KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Long-Term Investments: 2018

Historic Long-Term Investments for Esperion Therapeutics (ESPR) over the last 1 years, with Dec 2018 value amounting to $243,000.

  • Esperion Therapeutics' Long-Term Investments fell 27.05% to $30.9 million in Q1 2019 from the same period last year, while for Mar 2019 it was $30.9 million, marking a year-over-year decrease of 27.05%. This contributed to the annual value of $243,000 for FY2018, which is N/A change from last year.
  • Per Esperion Therapeutics' latest filing, its Long-Term Investments stood at $243,000 for FY2018.
  • Esperion Therapeutics' 5-year Long-Term Investments high stood at $243,000 for FY2018, and its period low was $243,000 during FY2018.
  • For the 1-year period, Esperion Therapeutics' Long-Term Investments averaged around $243,000, with its median value being $243,000 (2018).